Claims for Patent: 7,820,161

Summary for Patent: 7,820,161

Title:	Treatment of autoimmune diseases
Abstract:	Methods are disclosed of treating rheumatoid arthritis in a human comprising administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab and administering methotrexate to the human.
Inventor(s):	Curd; John G. (Hillsborough, CA), Kunkel; Lori A. (Oakland, CA), Grillo-Lopez; Antonio J. (Rancho Santa Fe, CA)
Assignee:	Biogen Idec, Inc. (Weston, MA) Genentech, Inc. (South San Francisco, CA)
Application Number:	09/564,288
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,820,161
Patent Claims:	1. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab; and (b) administering to the human methotrexate. 2. The method of claim 1, wherein each administration of the rituximab is a dose in the range from about 250 mg/m.sup.2 to about 1000 mg/m.sup.2. 3. The method of claim 1, comprising administering to the human a glucocorticosteroid. 4. The method of claim 1, comprising administering an initial dose of the rituximab followed by a subsequent dose, where the mg/m.sup.2 dose of the rituximab in the subsequent dose exceeds the mg/m.sup.2 dose of the rituximab in the initial dose. 5. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of an antibody that binds to the CD20 antigen on human B lymphocytes; and (b) administering to the human methotrexate; wherein the CD20 antibody administration consists of intravenous administration of the CD20 antibody, and the CD20 antibody is rituximab. 6. The method of claim 5, wherein each administration of the antibody is a dose in the range from about 250 mg/m.sup.2 to about 1000 mg/m.sup.2. 7. The method of claim 5, comprising administering to the human a glucocorticosteroid. 8. The method of claim 5, comprising administering an initial dose of the antibody followed by a subsequent dose, where the mg/m.sup.2 dose of the antibody in the subsequent dose exceeds the mg/m.sup.2 dose of the antibody in the initial dose. 9. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of an antibody that binds to the CD20 antigen on human B lymphocytes; and (b) administering to the human methotrexate; wherein the therapeutically effective amount of the CD20 antibody is administered intravenously, and the CD20 antibody is rituximab. 10. The method of claim 9, wherein each administration of the antibody is a dose in the range from about 250 mg/m.sup.2 to about 1000 mg/m.sup.2. 11. The method of claim 9, comprising administering to the human a glucocorticosteroid. 12. The method of claim 9, comprising administering an initial dose of the antibody followed by a subsequent dose, where the mg/m.sup.2 dose of the antibody in the subsequent dose exceeds the mg/m.sup.2 dose of the antibody in the initial dose.

Details for Patent 7,820,161

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2019-05-07
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2019-05-07
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2019-05-07